Systematic review and meta-analysis of narrow band imaging for non-muscle-invasive bladder cancer

原文： 2021 年发布于 Nutrients 11 卷第 1 期 239-249  浏览量：200次

作者： Gravestock P. Coulthard N. Veeratterapillay R. Heer R.

作者单位： Department of Urology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. Electronic address: marc_bjurlin@med.unc.edu. Department of Urology, New York University, New York, NY, USA. Health Sciences Library, NYU Langone Health, New York, NY, USA. Section on Tobacco, Alcohol and Drug Use, Department of Population Health, NYU School of Medicine, New York, NY, USA. Section on Tobacco, Alcohol and Drug Use, Department of Population Health, NYU School of Medicine, New York, NY, USA Office of Behavioral Health, Health + Hospitals, New York, NY, USA. Department of Environmental Medicine, New York University, New York, NY, USA.

归属分类：膀胱肿瘤治疗及预后证据

DOI： 10.3390/cancers13102496

关键词： external thermal field thermotherapy hyperthermic intravesical chemotherapy meta-analysis non-muscle invasive bladder cancer normal temperature intravesical chemotherapy thermal intravesical chemotherapy

Background: Neoadjuvant chemotherapy (NAC) could ameliorate the stage of locally advanced bladder cancer (LABC) which is defined in pT3/T4 and/or pN+, improve overall survival (OS) before radical cystectomy (RC). However, for LABC, the decision to use adjuvant chemotherapy (AC) after NAC and RC is still controversial. Methods: We performed a comprehensive search of the PubMed, Embase, and Cochrane Library databases for literature that reported prognosis after using AC following NAC and RC. Cumulative analyses of hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were performed. We performed all analyses by Review Manager software, version 5.3, and Stata 15.0. Results: Six retrospective cohort studies were included, involving 4,346 patients. Pooled analysis results showed that using AC after NAC and RC can improve OS (HR =0.83, 95% CI: 0.74-0.94, P=0.002; I-2 =0%) and cancer-specific survival (CSS) (HR =0.56, 95% CI: 0.32-0.99, P=0.04; I-2 =0%) but cannot extend recurrence-free survival (RFS) (HR =0.52, 95% CI: 0.27-1.01, P=0.05; I-2 =53%) for LABC patients. Conclusions: This pooled analysis shows that AC after NAC and RC can improve the prognosis for patients with LABC.